The use of recombinant FVIIa in a patient with Glanzmann thrombasthenia with uncontrolled bleeding after tonsillectomy.

Abstract

Glanzmann's thrombasthenia is an inherited platelet function disorder caused by quantitative or qualitative defects of the platelet membrane glycoprotein IIb/IIIa complex. Activated recombinant factor VII (rFVIIa) has recently been used in the treatment of patients with Glanzmann's thrombasthenia. We report herein a 16-year-old boy with Glanzmann's thrombasthenia who did not respond to conservative treatment for excessive bleeding and hyperfibrinolysis after tonsillectomy and who was successfully treated with rFVIIa. We suggest that rFVIIa at repeated doses of 80-100 microg/kg may be used effectively in patients with Glanzmann's thrombasthenia having excessive bleeding associated with hyperfibrinolysis after tonsillectomy in addition to tranexamic acid treatment.

• Authors: Erol Erduran, Ayşe Aksoy, Dilek Zaman
• Journal: Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis (Blood Coagul Fibrinolysis) Vol. 20 Issue 3 Pg. 215-7 (Apr 2009) ISSN: 1473-5733 [Electronic] England
• PMID: 19657319 (Publication Type: Case Reports, Journal Article)

Chemical References

• Recombinant Proteins
• recombinant FVIIa
• Factor VIIa

Topics

• Adolescent
• Blood Loss, Surgical (prevention & control)
• Factor VIIa (therapeutic use)
• Humans
• Male
• Recombinant Proteins (therapeutic use)
• Thrombasthenia (physiopathology, therapy)
• Tonsillectomy (adverse effects)